Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLONASDAQ:AQSTNASDAQ:ICCCNASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.15-3.0%$1.36$0.86▼$3.78$250.45M0.64.59 million shs815,166 shsAQSTAquestive Therapeutics$2.75-1.6%$2.67$2.12▼$5.80$272.66M2.021.57 million shs269,973 shsICCCImmuCell$6.43+2.7%$5.38$3.34▼$6.84$58.11M0.2317,512 shs880 shsRZLTRezolute$4.05-2.6%$3.33$2.22▼$6.19$347.64M1.01589,500 shs182,046 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+3.51%+8.26%-23.38%-39.49%-49.36%AQSTAquestive Therapeutics+2.20%+21.83%-1.76%-0.36%-9.12%ICCCImmuCell+0.16%+1.29%+14.03%+18.56%+43.25%RZLTRezolute+5.32%+6.67%+7.77%-6.09%+0.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics3.7555 of 5 stars4.53.00.00.02.73.30.6AQSTAquestive Therapeutics1.2382 of 5 stars3.51.00.00.02.30.00.0ICCCImmuCell0.2202 of 5 stars0.03.00.00.02.00.00.0RZLTRezolute2.9205 of 5 stars3.62.00.00.03.34.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$8.44637.51% UpsideAQSTAquestive Therapeutics 3.00Buy$10.67288.59% UpsideICCCImmuCell 0.00N/AN/AN/ARZLTRezolute 3.14Buy$12.14199.68% UpsideCurrent Analyst Ratings BreakdownLatest ICCC, RZLT, AQST, and ALLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ALLOAllogene TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/15/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.005/14/2025ALLOAllogene TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/2/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$22K11,383.95N/AN/A$3.04 per share0.38AQSTAquestive Therapeutics$54.23M5.03N/AN/A($1.59) per share-1.73ICCCImmuCell$27.30M2.13N/AN/A$3.23 per share1.99RZLTRezoluteN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$327.27M-$1.23N/AN/AN/AN/A-52.13%-41.29%8/6/2025 (Estimated)AQSTAquestive Therapeutics-$7.87M-$0.59N/AN/AN/A-59.75%N/A-33.96%8/5/2025 (Estimated)ICCCImmuCell-$5.78M-$0.07N/A∞N/A-15.99%-15.32%-8.81%8/11/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.27%-62.41%N/ALatest ICCC, RZLT, AQST, and ALLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ICCCImmuCellN/A$0.16N/A$0.16N/A$8.07 million5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A5/12/2025Q1 2025AQSTAquestive Therapeutics-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million3/13/2025Q4 2024ALLOAllogene Therapeutics-$0.34-$0.28+$0.06-$0.28$0.01 millionN/A3/5/2025Q4 2024AQSTAquestive Therapeutics-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.359.35AQSTAquestive TherapeuticsN/A6.375.91ICCCImmuCell0.363.111.44RZLTRezoluteN/A9.309.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%AQSTAquestive Therapeutics32.45%ICCCImmuCell13.47%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%AQSTAquestive Therapeutics8.35%ICCCImmuCell6.60%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310218.73 million158.72 millionOptionableAQSTAquestive Therapeutics16099.33 million84.02 millionOptionableICCCImmuCell709.04 million8.32 millionNot OptionableRZLTRezolute4085.52 million49.40 millionOptionableICCC, RZLT, AQST, and ALLO HeadlinesRecent News About These CompaniesRezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital HyperinsulinismMay 28 at 8:00 AM | globenewswire.comMan Group plc Makes New $425,000 Investment in Rezolute, Inc. (NASDAQ:RZLT)May 28 at 3:51 AM | marketbeat.comWoodline Partners LP Acquires 1,052,002 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 26, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Lowered to "Sell" Rating by Wall Street ZenMay 24, 2025 | marketbeat.comBrokerages Set Rezolute, Inc. (NASDAQ:RZLT) PT at $12.14May 23, 2025 | americanbankingnews.comOMERS ADMINISTRATION Corp Invests $372,000 in Rezolute, Inc. (NASDAQ:RZLT)May 22, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from BrokeragesMay 22, 2025 | marketbeat.comRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 21, 2025 | finanznachrichten.deHC Wainwright Analysts Lift Earnings Estimates for RezoluteMay 21, 2025 | marketbeat.comRezolute, Inc. (RZLT): Analysts See 260% Upside PotentialMay 20, 2025 | finance.yahoo.comCubist Systematic Strategies LLC Sells 92,168 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 20, 2025 | marketbeat.comPoint72 Europe London LLP Purchases New Position in Rezolute, Inc. (NASDAQ:RZLT)May 18, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Shares Purchased by Dimensional Fund Advisors LPMay 18, 2025 | marketbeat.comRezolute (RZLT) to Release Earnings on WednesdayMay 16, 2025 | marketbeat.comRezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia TreatmentMay 16, 2025 | nasdaq.comRezolute, Inc. (NASDAQ:RZLT) Shares Purchased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Boosts Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT)May 14, 2025 | marketbeat.comJ. Goldman & Co LP Takes $1.14 Million Position in Rezolute, Inc. (NASDAQ:RZLT)May 14, 2025 | marketbeat.comRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Sells 272,368 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 13, 2025 | marketbeat.comSusquehanna International Group LLP Buys 788,349 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICCC, RZLT, AQST, and ALLO Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.14 -0.04 (-2.97%) As of 12:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Aquestive Therapeutics NASDAQ:AQST$2.74 -0.05 (-1.61%) As of 12:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.ImmuCell NASDAQ:ICCC$6.43 +0.17 (+2.72%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Rezolute NASDAQ:RZLT$4.05 -0.11 (-2.60%) As of 12:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
